Pde5 Inhibition Reduced Blood Pressure and Alleviated Target Organ Damage in Chronic Intermittent Hypoxia
Open Access
- 22 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 84 (1) , 81-91
Abstract
The role of phosphodiesterase 5 (Pde5) in obstructive sleep apnea–induced damage remains unclear. Our study aimed to investigate the role of Pde5 in the chronic intermittent hypoxia (CIH) model. C57BL/6J wild-type (WT) mice (n = 48) and Pde5 knockout (Pde5−/−) mice (n = 24) were randomly assigned to CIH group and room air group. After 6 weeks, some WT mice (n = 24) in CIH group were given sildenafil or saline gavage for another 4 weeks. Blood pressure was regularly measured during the experiment. Echocardiography was used to estimate cardiac function. We collected organs from each group of mice and measured their physical indicators. Histochemical staining was used to explore the size of cardiomyocyte and fibrosis area of various organs. Cyclic guanosine monophosphate and malondialdehyde concentrations in serum were measured by ELISA assay. Compared with the RA-treated group, the 6-week CIH resulted in a significant increase in blood pressure, altered heart structure, and reduced serum cyclic guanosine monophosphate in WT mice. Pde5−/− mice and sildenafil intragastric administration significantly reduced systolic blood pressure in CIH condition and attenuated the damage of target organs. In CIH model, we found that the cardiomyocyte size and fibrosis area of heart and kidney significantly reduced in Pde5−/− groups. Besides, endogenous and exogenous inhibition of Pde5 reduced malondialdehyde level and inflammatory and oxidative stress markers expression in CIH condition. In this study, we found that Pde5 inhibition could reduce blood pressure and alleviate target organ damage in the CIH model, which may be mediated through the oxidative stress pathway.Keywords
Funding Information
- National Natural Science Foundation of China (81970292)
- National Natural Science Foundation of China (82270258)
- National Natural Science Foundation of China (82100260)
This publication has 44 references indexed in Scilit:
- American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac DeathCirculation, 2008
- Obstructive Sleep Apnea and Resistant HypertensionChest, 2007
- Effect of Regular Phosphodiesterase Type 5 Inhibition in HypertensionHypertension, 2006
- A Double-blind, Placebo-Controlled, Crossover Study of Sildenafil in Obstructive Sleep ApneaArchives of internal medicine (1960), 2006
- Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated ratsEuropean Journal of Pharmacology, 2006
- Obstructive Sleep Apnea Syndrome Affects Left Ventricular Diastolic FunctionCirculation, 2005
- Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophyNature Medicine, 2005
- cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent MechanismCirculation Research, 2005
- Prospective Study of the Association between Sleep-Disordered Breathing and HypertensionNew England Journal of Medicine, 2000
- Cardiac Hypertrophy in Obstructive Sleep Apnea SyndromeChest, 1995